[{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Nichi-Iko Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Limaprost Alfadex","moa":"PGE2","graph1":"Neurology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Camostat","moa":"Proteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Landiolol Hydrochloride","moa":"Beta-1 adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.51000000000000001,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Roche"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Camostat","moa":"Proteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Chordia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"CTX-177","moa":"MALT1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ono Pharmaceutical","amount2":0.51000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"Oral","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Ribon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"RBN-2397","moa":"PARP7","graph1":"Oncology","graph2":"Phase I","graph3":"Ono Pharmaceutical","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Bristol-Myers Squibb"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ono Pharmaceutical \/ Ono Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Ono Pharma"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Neurimmune","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Human-derived Monoclonal Antibodies","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ono Pharmaceutical","amount2":0.28000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Iktos","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceuticals"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Fate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Expanded Collaboration","leadProduct":"IPSC-derived CAR NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ ONO Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Ono Pharmaceutical \/ ONO Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3 receptor","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Memo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Fate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"ONO-8250","moa":"HER2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ ONO Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Ono Pharmaceutical \/ ONO Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Captor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ono Pharmaceutical","amount2":0.20000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Equillium","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Itolizumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"PrecisionLife","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"RP-2119","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ono Pharmaceutical","amount2":0.17999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"KSQ Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"CUE-401","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ono Pharmaceutical","amount2":0.22,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.22,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Macomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tirabrutinib Hydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Personalis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Adimab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Turbine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"NM49","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Shattuck Labs","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Ono Pharmaceutical","amount2":0.23000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"InveniAI","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Sibylla Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tirabrutinib Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"EVQLV","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Prism Biolab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ ONO Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Ono Pharmaceutical \/ ONO Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":2.3999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":2.3999999999999999,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ ONO Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ ONO Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":2.3999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":2.3999999999999999,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Turbine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Ligachem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"LCB97","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ono Pharmaceutical","amount2":0.69999999999999996,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Equillium","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Termination","leadProduct":"Itolizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Ono Pharmaceutical \/ Ono Pharmaceutical"}]
Find Clinical Drug Pipeline Developments & Deals by Ono Pharmaceutical
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
